353 related articles for article (PubMed ID: 25173478)
1. Baculovirus-expressed virus-like particle vaccine in combination with DNA encoding the fusion protein confers protection against respiratory syncytial virus.
Lee JS; Kwon YM; Hwang HS; Lee YN; Ko EJ; Yoo SE; Kim MC; Kim KH; Cho MK; Lee YT; Lee YR; Quan FS; Kang SM
Vaccine; 2014 Oct; 32(44):5866-74. PubMed ID: 25173478
[TBL] [Abstract][Full Text] [Related]
2. Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells.
Kim KH; Lee YT; Hwang HS; Kwon YM; Kim MC; Ko EJ; Lee JS; Lee Y; Kang SM
J Virol; 2015 Nov; 89(22):11692-705. PubMed ID: 26355098
[TBL] [Abstract][Full Text] [Related]
3. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM
Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590
[TBL] [Abstract][Full Text] [Related]
4. Co-immunization with virus-like particle and DNA vaccines induces protection against respiratory syncytial virus infection and bronchiolitis.
Hwang HS; Kwon YM; Lee JS; Yoo SE; Lee YN; Ko EJ; Kim MC; Cho MK; Lee YT; Jung YJ; Lee JY; Li JD; Kang SM
Antiviral Res; 2014 Oct; 110():115-23. PubMed ID: 25110201
[TBL] [Abstract][Full Text] [Related]
5. Combined virus-like particle and fusion protein-encoding DNA vaccination of cotton rats induces protection against respiratory syncytial virus without causing vaccine-enhanced disease.
Hwang HS; Lee YT; Kim KH; Park S; Kwon YM; Lee Y; Ko EJ; Jung YJ; Lee JS; Kim YJ; Lee YN; Kim MC; Cho M; Kang SM
Virology; 2016 Jul; 494():215-24. PubMed ID: 27123586
[TBL] [Abstract][Full Text] [Related]
6. Virus-like particle vaccines containing F or F and G proteins confer protection against respiratory syncytial virus without pulmonary inflammation in cotton rats.
Hwang HS; Kim KH; Lee Y; Lee YT; Ko EJ; Park S; Lee JS; Lee BC; Kwon YM; Moore ML; Kang SM
Hum Vaccin Immunother; 2017 May; 13(5):1031-1039. PubMed ID: 28129031
[TBL] [Abstract][Full Text] [Related]
7. Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice.
Quan FS; Kim Y; Lee S; Yi H; Kang SM; Bozja J; Moore ML; Compans RW
J Infect Dis; 2011 Oct; 204(7):987-95. PubMed ID: 21881112
[TBL] [Abstract][Full Text] [Related]
8. Chimeric virus-like particles containing a conserved region of the G protein in combination with a single peptide of the M2 protein confer protection against respiratory syncytial virus infection.
Qiao L; Zhang Y; Chai F; Tan Y; Huo C; Pan Z
Antiviral Res; 2016 Jul; 131():131-40. PubMed ID: 27154395
[TBL] [Abstract][Full Text] [Related]
9. Alternative Virus-Like Particle-Associated Prefusion F Proteins as Maternal Vaccines for Respiratory Syncytial Virus.
Blanco JCG; Fernando LR; Zhang W; Kamali A; Boukhvalova MS; McGinnes-Cullen L; Morrison TG
J Virol; 2019 Dec; 93(23):. PubMed ID: 31511382
[TBL] [Abstract][Full Text] [Related]
10. A single intranasal administration of virus-like particle vaccine induces an efficient protection for mice against human respiratory syncytial virus.
Jiao YY; Fu YH; Yan YF; Hua Y; Ma Y; Zhang XJ; Song JD; Peng XL; Huang J; Hong T; He JS
Antiviral Res; 2017 Aug; 144():57-69. PubMed ID: 28529001
[TBL] [Abstract][Full Text] [Related]
11. Additive protection induced by mixed virus-like particles presenting respiratory syncytial virus fusion or attachment glycoproteins.
Lee S; Quan FS; Kwon Y; Sakamoto K; Kang SM; Compans RW; Moore ML
Antiviral Res; 2014 Nov; 111():129-35. PubMed ID: 25239522
[TBL] [Abstract][Full Text] [Related]
12. Soluble F proteins exacerbate pulmonary histopathology after vaccination upon respiratory syncytial virus challenge but not when presented on virus-like particles.
Lee Y; Lee YT; Ko EJ; Kim KH; Hwang HS; Park S; Kwon YM; Kang SM
Hum Vaccin Immunother; 2017 Nov; 13(11):2594-2605. PubMed ID: 28854003
[TBL] [Abstract][Full Text] [Related]
13. Virus-like particle vaccine primes immune responses preventing inactivated-virus vaccine-enhanced disease against respiratory syncytial virus.
Hwang HS; Lee YT; Kim KH; Ko EJ; Lee Y; Kwon YM; Kang SM
Virology; 2017 Nov; 511():142-151. PubMed ID: 28846899
[TBL] [Abstract][Full Text] [Related]
14. Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology.
Murawski MR; McGinnes LW; Finberg RW; Kurt-Jones EA; Massare MJ; Smith G; Heaton PM; Fraire AE; Morrison TG
J Virol; 2010 Jan; 84(2):1110-23. PubMed ID: 19889768
[TBL] [Abstract][Full Text] [Related]
15. A respiratory syncytial virus (RSV) vaccine based on parainfluenza virus 5 (PIV5).
Phan SI; Chen Z; Xu P; Li Z; Gao X; Foster SL; Teng MN; Tripp RA; Sakamoto K; He B
Vaccine; 2014 May; 32(25):3050-7. PubMed ID: 24717150
[TBL] [Abstract][Full Text] [Related]
16. A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without Th2 associated vaccine-enhanced disease.
Lindell DM; Morris SB; White MP; Kallal LE; Lundy PK; Hamouda T; Baker JR; Lukacs NW
PLoS One; 2011; 6(7):e21823. PubMed ID: 21789184
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice.
Kamphuis T; Meijerhof T; Stegmann T; Lederhofer J; Wilschut J; de Haan A
PLoS One; 2012; 7(5):e36812. PubMed ID: 22590614
[TBL] [Abstract][Full Text] [Related]
18. Immunization with Low Doses of Recombinant Postfusion or Prefusion Respiratory Syncytial Virus F Primes for Vaccine-Enhanced Disease in the Cotton Rat Model Independently of the Presence of a Th1-Biasing (GLA-SE) or Th2-Biasing (Alum) Adjuvant.
Schneider-Ohrum K; Cayatte C; Bennett AS; Rajani GM; McTamney P; Nacel K; Hostetler L; Cheng L; Ren K; O'Day T; Prince GA; McCarthy MP
J Virol; 2017 Apr; 91(8):. PubMed ID: 28148790
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats.
Kamphuis T; Shafique M; Meijerhof T; Stegmann T; Wilschut J; de Haan A
Vaccine; 2013 Apr; 31(17):2169-76. PubMed ID: 23499594
[TBL] [Abstract][Full Text] [Related]
20. Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats.
Widjojoatmodjo MN; Bogaert L; Meek B; Zahn R; Vellinga J; Custers J; Serroyen J; Radošević K; Schuitemaker H
Vaccine; 2015 Oct; 33(41):5406-5414. PubMed ID: 26319741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
